Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmeris… Read more
Fagron NV (ARSUF) - Total Assets
Latest total assets as of June 2025: $1.12 Billion USD
Based on the latest financial reports, Fagron NV (ARSUF) holds total assets worth $1.12 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fagron NV - Total Assets Trend (2013–2024)
This chart illustrates how Fagron NV’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Fagron NV - Asset Composition Analysis
Current Asset Composition (December 2024)
Fagron NV's total assets of $1.12 Billion consist of 33.5% current assets and 66.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.6% |
| Accounts Receivable | $81.96 Million | 7.6% |
| Inventory | $136.96 Million | 12.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $61.40 Million | 5.7% |
| Goodwill | $446.95 Million | 41.3% |
Asset Composition Trend (2013–2024)
This chart illustrates how Fagron NV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fagron NV's current assets represent 33.5% of total assets in 2024, a decrease from 38.9% in 2013.
- Cash Position: Cash and equivalents constituted 10.6% of total assets in 2024, down from 16.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, unchanged from 46.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 41.3% of total assets.
Fagron NV Competitors by Total Assets
Key competitors of Fagron NV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Fagron NV - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Fagron NV generates 0.80x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Fagron NV generates $7.43 in net profit.
Fagron NV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.76 | 1.74 | 1.14 |
| Quick Ratio | 1.06 | 1.08 | 0.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $161.21 Million | $ 147.76 Million | $ 33.39 Million |
Fagron NV - Advanced Valuation Insights
This section examines the relationship between Fagron NV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.26 |
| Latest Market Cap to Assets Ratio | 1.20 |
| Asset Growth Rate (YoY) | 7.6% |
| Total Assets | $1.08 Billion |
| Market Capitalization | $1.30 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Fagron NV's assets above their book value (1.20 x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Fagron NV's assets grew by 7.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Fagron NV (2013–2024)
The table below shows the annual total assets of Fagron NV from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.08 Billion | +7.60% |
| 2023-12-31 | $1.01 Billion | +3.70% |
| 2022-12-31 | $971.01 Million | +21.31% |
| 2021-12-31 | $800.42 Million | +6.32% |
| 2020-12-31 | $752.83 Million | -6.04% |
| 2019-12-31 | $801.24 Million | +17.35% |
| 2018-12-31 | $682.77 Million | +14.94% |
| 2017-12-31 | $594.05 Million | -31.57% |
| 2016-12-31 | $868.05 Million | +25.92% |
| 2015-12-31 | $689.38 Million | -41.48% |
| 2014-12-31 | $1.18 Billion | +46.39% |
| 2013-12-31 | $804.69 Million | -- |